Amy E Caruso Brown1, Edwin J Asturias2, Mario Melgar3, Federico A Antillon-Klussmann3, Pamela Mettler4, Myron J Levin5. 1. Center for Bioethics and Humanities and Department of Pediatrics, SUNY Upstate Medical University, Syracuse, USA. brownamy@upstate.edu. 2. Center for Global Health and Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA. 3. National Unit of Pediatric Oncology, Guatemala City, Guatemala. 4. Department of Biostatistics and Informatics, Colorado Biostatistics Consortium, Colorado School of Public Health, Aurora, Colorado, USA. 5. Section of Pediatric Infectious Diseases, Department of Pediatrics, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
BACKGROUND: Varicella-zoster virus infection is associated with significant morbidity and mortality in immune-compromised children, despite treatment with antiviral agents. Universal varicella vaccine programs have significantly decreased this risk in many highincome countries, but in most low-income and middleincome countries, the burden of varicella in children treated for malignancy is poorly defined. METHODS: We retrospectively reviewed records of children at the National Unit of Pediatric Oncology (UNOP) in Guatemala diagnosed with varicella between January 2009 and March 2013 in order to calculate incidence of varicella and evaluate morbidity, mortality, treatment interruption, and cost. RESULTS: Fifty-nine cases of varicella were identified. Incidence was 23.4 cases per 1000 person-years (p-y). 66.1% of cases occurred in children with leukemia (median age 5.2 years; interquantile range 3.4-7 years) and 41.0% of these occurred during maintenance therapy. Source of exposure was identified for 14/59 (23.7%) children. Most were hospitalized (71.2%) and given intravenous acyclovir (64.4%). Eight (13.6%) children required critical care, and two (3.4%) died from disseminated varicella with multiorgan failure. Chemotherapy was delayed or omitted due to varicella in 50%. No significant differences in outcomes based on nutritional and immunologic status were detected. The minimum average cost of treatment per episode was 598.75 USD. CONCLUSIONS: Varicella is a significant problem in children treated for cancer in Guatemala, where effective post-exposure prophylaxis is limited. In the absence of universal varicella vaccination, strategies to improve recognition of exposure and the future use of novel inactivated vaccines currently under investigation in clinical trials could mitigate this burden.
BACKGROUND:Varicella-zoster virus infection is associated with significant morbidity and mortality in immune-compromised children, despite treatment with antiviral agents. Universal varicella vaccine programs have significantly decreased this risk in many highincome countries, but in most low-income and middleincome countries, the burden of varicella in children treated for malignancy is poorly defined. METHODS: We retrospectively reviewed records of children at the National Unit of Pediatric Oncology (UNOP) in Guatemala diagnosed with varicella between January 2009 and March 2013 in order to calculate incidence of varicella and evaluate morbidity, mortality, treatment interruption, and cost. RESULTS: Fifty-nine cases of varicella were identified. Incidence was 23.4 cases per 1000 person-years (p-y). 66.1% of cases occurred in children with leukemia (median age 5.2 years; interquantile range 3.4-7 years) and 41.0% of these occurred during maintenance therapy. Source of exposure was identified for 14/59 (23.7%) children. Most were hospitalized (71.2%) and given intravenous acyclovir (64.4%). Eight (13.6%) children required critical care, and two (3.4%) died from disseminated varicella with multiorgan failure. Chemotherapy was delayed or omitted due to varicella in 50%. No significant differences in outcomes based on nutritional and immunologic status were detected. The minimum average cost of treatment per episode was 598.75 USD. CONCLUSIONS: Varicella is a significant problem in children treated for cancer in Guatemala, where effective post-exposure prophylaxis is limited. In the absence of universal varicella vaccination, strategies to improve recognition of exposure and the future use of novel inactivated vaccines currently under investigation in clinical trials could mitigate this burden.
Authors: Angel Paternina-Caicedo; Fernando De la Hoz-Restrepo; Oscar Gamboa-Garay; Carlos Castañeda-Orjuela; Martha Velandia-González; Nelson Alvis-Guzmán Journal: Vaccine Date: 2012-11-19 Impact factor: 3.641
Authors: Smita Bhatia; Wendy Landier; Muyun Shangguan; Lindsey Hageman; Alexandra N Schaible; Andrea R Carter; Cara L Hanby; Wendy Leisenring; Yutaka Yasui; Nancy M Kornegay; Leo Mascarenhas; A Kim Ritchey; Jacqueline N Casillas; David S Dickens; Jane Meza; William L Carroll; Mary V Relling; F Lennie Wong Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Monika L Metzger; Scott C Howard; Ligia C Fu; Armando Peña; Rene Stefan; Michael L Hancock; Zhe Zhang; Ching Hon Pui; Judy Wilimas; Raul C Ribeiro Journal: Lancet Date: 2003-08-30 Impact factor: 79.321